: Gained 103% , evolving from a rare-disease specialist into a large-cap biotech giant. Blue-Chip & Dividend Leaders
The year’s biggest winners were often clinical-stage companies that secured major regulatory wins or licensing deals.
: A top pick for dividends (yielding ~4.2%) and growth, with shares rising 45% in 2017 driven by Humira and its cancer drug pipeline.
: Soared over 440% after announcing a gene therapy partnership with Pfizer .
: Held its position as the world's largest pharma company by market cap ($387B in 2017). ⚠️ Key Trends & Risks
